The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Zheyong Huang; Jiatian Cao; Yumeng Yao; Xuejuan Jin; Zhe Luo; Yuan Xue; Chouwen Zhu; Yanan Song; Ying Wang; Yunzeng Zou; Juying Qian; Kaihuan Yu; Hui Gong; Junbo Ge

doi:10.21037/atm.2020.03.229

The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension

Ann Transl Med. 2020 Apr;8(7):430. doi: 10.21037/atm.2020.03.229.

Authors

Zheyong Huang¹, Jiatian Cao¹, Yumeng Yao², Xuejuan Jin¹, Zhe Luo³, Yuan Xue³, Chouwen Zhu⁴, Yanan Song¹, Ying Wang¹, Yunzeng Zou¹, Juying Qian¹, Kaihuan Yu⁵, Hui Gong¹, Junbo Ge¹

Affiliations

¹ Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
² Department of Infection Disease, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
³ Department of Critical Medicine, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
⁴ Department of Gastroenterology, Zhongshan Hospital, Fudan University, Shanghai 200032, China.
⁵ Department of Hepatobiliary Surgery, Renmin Hospital of Wuhan University, Wuhan 430200, China.

Abstract

Background: Coronavirus disease 2019 (COVID-19), caused by a novel coronavirus (designated as SARS-CoV-2) has become a pandemic worldwide. Based on the current reports, hypertension may be associated with increased risk of sever condition in hospitalized COVID-19 patients. Angiotensin-converting enzyme 2 (ACE2) was recently identified to functional receptor of SARS-CoV-2. Previous experimental data revealed ACE2 level was increased following treatment with ACE inhibitors (ACEIs) and angiotensin receptor blockers (ARBs). Currently doctors concern whether these commonly used renin-angiotensin system (RAS) blockers-ACEIs/ARBs may increase the severity of COVID-19.

Methods: We extracted data regarding 50 hospitalized hypertension patients with laboratory confirmed COVID-19 in the Renmin Hospital of Wuhan University from Feb 7 to Mar 03, 2020. These patients were grouped into RAS blockers group (Group A, n=20) and non-RAS blockers group (Group B, n=30) according to the basic blood pressure medications. All patients continued to use pre-admission antihypertensive drugs. Clinical severity (symptoms, laboratory and chest CT findings, etc.), clinical course, and short time outcome were analyzed after hospital admission.

Results: Ten (50%) and seventeen (56.7%) of the Group A and Group B participants were males (P=0.643), and the average age was 52.65±13.12 and 67.77±12.84 years (P=0.000), respectively. The blood pressure of both groups was under effective control. There was no significant difference in clinical severity, clinical course and in-hospital mortality between Group A and Group B. Serum cardiac troponin I (cTnI) (P=0.03), and N-terminal (NT)-pro hormone BNP (NT-proBNP) (P=0.04) showed significant lower level in Group A than in Group B. But the patients with more than 0.04ng/mL or elevated NT-proBNP level had no statistical significance between the two groups. In patients over 65 years or under 65 years, cTnI or NT-proBNP level showed no difference between the two groups.

Conclusions: We observed there was no obvious difference in clinical characteristics between RAS blockers and non-RAS blockers groups. These data suggest ACEIs/ARBs may have few effects on increasing the clinical severe conditions of COVID-19.

Keywords: ACE inhibitors/angiotensin receptor blockers (ACEIs/ARBs); Coronavirus disease 2019 (COVID-19); angiotensin-converting enzyme 2 (ACE2); hypertension; renin-angiotensin system blockers (RAS blockers).